A longer course of varenicline therapy improves smoking cessation rates

Abstract

Smoking exerts strong dose-dependent increases in cardiovascular risk and mortality, and quitting can profoundly decrease these risks. Varenicline attenuates nicotine addiction by reducing withdrawal symptoms and cravings. A meta-analysis performed addressed whether a longer duration of varenicline is associated with better abstinence rates than shorter courses of treatment. For this meta-analysis, a literature search was performed to identify randomized controlled trials investigating the efficacy of the smoking cessation agent varenicline. The association between abstinence and duration of treatment was analyzed using fixed-effect meta-regression. Five randomized controlled trials were identified and included in this meta-analysis. A highly significant relationship (P<.001) was found between the length of exposure to varenicline and abstinence rate. Cessation rates were approximately twice as high with varenicline treatment of 24 weeks compared to 6 weeks. In conclusion, a meta-analysis of randomized controlled trials suggests that longer duration of varenicline therapy improves long-term abstinence rates.